Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eplontersen in ATTR-CM
NCT04136171Phase 3Completed
- Sponsor
- Ionis Pharmaceuticals
- Start
- Mar 2020
- Primary completion
- Mar 2026
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 21
01
Overview
A Phase 3 trial of eplontersen in transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), sponsored by Ionis Pharmaceuticals. Started Mar 2020; status: completed.
02
Drugs
eplontersen
03
Conditions
transthyretin-mediated amyloid cardiomyopathy (ATTR-CM)
Beyond the preview
Go deeper on NCT04136171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04136171.